Clary Clish is Senior Director of Metabolomics and an Institute Scientist at the Broad Institute of MIT and Harvard. His lab works to develop and apply technologies for the systematic analysis of metabolites and small molecules within biological specimens. His research is highly collaborative and broadly aims to advance our understanding of the role of metabolism in normal physiology and disease. Current projects range in scope from dissecting metabolic dependencies in cancer to identification of early derangements of metabolism that precede disease, or clinical symptoms of disease, in human cohorts.
Prior to joining the Broad Institute, Clish held senior and executive management positions in the biotechnology industry from 2001-2008, including Vice President of Discovery at Gene Logic Inc. and Director of Metabolite Biochemistry at Beyond Genomics Inc. From 1997-2001, Clish was a postdoctoral fellow and instructor in the laboratory of Dr. Charles Serhan at the Center for Experimental Therapeutics and Reperfusion Injury at Brigham & Women’s Hospital. In the Serhan laboratory, his work focused on understanding the roles of lipid mediators in acute inflammation and its resolution, including his discovery and characterization of a novel class of anti-inflammatory lipid mediators that have since been named “resolvins.”
He was awarded an Honorary Fellowship from the Metabolomics Society in 2024.